Key Takeaways
- DSCSA compliance for Indian pharma exporters requires integrated serialization and electronic traceability solutions for successful US exports.
- Manufacturers must validate that DataMatrix codes are readable and match packaging records for effective DSCSA compliance.
- Effective EPCIS data exchange is crucial for accurate serialization during the pharmaceutical supply chain process.
- Regular testing of trading-partner connectivity ensures seamless data exchange vital for DSCSA serialization requirements.
- Preparation for the November 2026 deadline includes proactive measures to verify serialization workflows and exception handling.
For Indian pharmaceutical manufacturers exporting prescription medicines to the United States, DSCSA readiness now goes beyond simply printing serialized codes. DSCSA compliance for Indian pharma exporters depends on accurate package identification, reliable electronic traceability and smooth data exchange with US trading partners.
Manufacturers should also note that November 2026 is no longer a general compliance deadline for all supply-chain participants.
Understanding the DSCSA Deadline Situation
The Drug Supply Chain Security Act introduced electronic and interoperable product tracing requirements across the US pharmaceutical supply chain.
For eligible manufacturers and repackagers, the FDA phased exemption ended on May 27, 2025. The wholesale distributor exemption ended on August 27, 2025, while the exemption for larger dispensers ended on November 27, 2025.
November 2026 had remained important for qualifying small business dispensers, but FDA later extended certain exemptions for eligible small dispensers through November 27, 2027.
For Indian manufacturers, the key point is clear: DSCSA serialization requirements should already be integrated into US-bound packaging operations.
What Indian Pharma Exporters Must Verify
Installing a serialization machine alone does not mean the entire process is ready for US distribution.
Before releasing products, manufacturers should verify:
- Product identifiers are correctly printed.
- DataMatrix codes are readable.
- Serial numbers, lot details and expiry information match packaging records.
- Incorrect or unreadable codes are detected.
- Serialization records are stored and retrievable.
- Aggregation relationships are accurate where used.
- Data can be exchanged with relevant trading partners.
These checks are important for pharmaceutical serialization for US exports because problems can arise at the packaging, data or integration level.
Verify Package-Level Electronic Traceability
A central objective of DSCSA is electronic package-level tracing.
This means exporters must manage both the physical pharmaceutical package and the corresponding electronic information.
A suitable DSCSA track and trace solution should connect production-line serialization with electronic records, verification events, aggregation and downstream data requirements.
Manufacturers should treat serialization as an integrated production and supply-chain process rather than as a standalone coding activity.
Check DataMatrix and Product Identifier Accuracy
DataMatrix quality is a critical part of pharmaceutical serialization.
Manufacturers should routinely verify:
- DataMatrix readability
- Serialized product information
- Lot and expiry details
- Human-readable text
- Print quality
- Invalid or duplicate codes
- Rejected pack handling
These controls support DSCSA serialization requirements by reducing the possibility of incorrect serialized packs moving into distribution.
Verify Serialization and Aggregation Workflows
Serialization gives each saleable pharmaceutical pack a unique identity. Aggregation can then connect individual packs with cartons, cases or pallets.
A typical workflow includes:
- Generate or receive serialization data.
- Print unique identifiers.
- Inspect codes and printed information.
- Reject incorrect packs.
- Create aggregation relationships where required.
- Store serialization records.
- Exchange relevant data with downstream systems.
For pharmaceutical serialization for US exports, these stages should work together as one connected workflow.
Confirm EPCIS Data Exchange Readiness
Physical serialization alone is not enough.
Electronic product events also need to move between systems and trading partners. EPCIS data exchange is commonly used in pharmaceutical serialization environments to communicate serialized event information.
Before commercial shipments, manufacturers should verify:
- EPCIS message generation
- Product and master data accuracy
- Trading-partner connectivity
- File validation
- Error handling
- Data reconciliation
Testing EPCIS data exchange before regular shipments can help identify integration problems before they affect supply-chain operations.
Test Trading-Partner Connectivity
A packaging line may serialize every carton correctly while electronic data exchange with a US customer or distributor still fails.
For this reason, DSCSA compliance for Indian pharma exporters should include end-to-end connectivity testing.
Manufacturers should confirm that both sides can correctly send, receive and interpret serialized information. Procedures for handling missing records, failed messages and data corrections should also be clearly defined.
Build Exception Handling Into Daily Operations
Serialization systems can encounter routine exceptions such as:
- Damaged cartons
- Unreadable codes
- Duplicate serial numbers
- Rejected packs
- Reworked products
- Decommissioned serial numbers
- Aggregation mismatches
A reliable DSCSA track and trace solution should help manage these events while keeping physical products aligned with electronic records.
Internal SOPs should also clearly define how exceptions are reviewed, corrected and reconciled before product release.
How Sun Teknovation Supports Pharma Serialization
Sun Teknovation Pvt Ltd. provides pharmaceutical serialization, Track & Trace, aggregation and machine-vision solutions for regulated packaging environments.
Its portfolio includes Online Track & Trace, Offline Track & Trace, aggregation systems and eTrack L3 plant-level serialization and aggregation software.
Relevant capabilities include DataMatrix inspection, OCR/OCV verification, line-level serialization, aggregation workflows and electronic data handling.
For manufacturers evaluating a DSCSA track and trace solution, these capabilities can help connect packaging-line identification with broader traceability processes.
Do Not Treat an Exemption as an Export Strategy
FDA exemptions apply only to specific categories of trading partners and defined circumstances.
The extended date for qualifying small dispensers does not mean manufacturers should delay their own readiness.
For DSCSA compliance for Indian pharma exporters, packaging, QA, regulatory, IT and supply-chain teams should work from the same serialization framework.
Manufacturers should regularly review DSCSA serialization requirements, packaging performance and EPCIS data exchange rather than treating compliance as a one-time project.
Final DSCSA Readiness Checklist
Before shipping pharmaceutical products to the US, exporters should verify:
- Serialization systems are active.
- Product identifiers are correctly printed.
- DataMatrix codes are inspected.
- Physical packs match electronic records.
- Aggregation data is accurate where used.
- Rejected and reworked packs are managed correctly.
- Trading-partner connectivity has been tested.
- Serialization records can be retrieved when required.
This provides a practical framework for companies managing pharmaceutical serialization for US exports.
Why Choose Us
Sun Teknovation Pvt Ltd. supports pharmaceutical manufacturers with machine vision, serialization, online and offline Track & Trace, aggregation and plant-level serialization software. Our solutions cover DataMatrix inspection, OCR/OCV verification, serialization workflows, aggregation and electronic traceability. We help pharmaceutical manufacturers build connected packaging and traceability processes for regulated domestic and export markets.
Conclusion
Indian pharmaceutical manufacturers should not wait for November 2026 to review DSCSA readiness. Manufacturer and repackager exemptions ended earlier, while the previously relevant November 2026 date for qualifying small dispensers has moved to November 27, 2027. Exporters should now focus on package-level identification, serialization controls, aggregation, trading-partner connectivity and EPCIS data exchange. A connected traceability infrastructure can support more reliable US-bound pharmaceutical operations.
Planning to implement or upgrade serialization systems for the US market?
Sun Teknovation Pvt Ltd. can support your packaging operations with serialization, aggregation, DataMatrix inspection, machine vision and pharmaceutical Track & Trace solutions.
Call us: +91 98982 45695 or Email: connect@sunteknovation.com.
Frequently Asked Questions
Ajay Roshania
Co-Founder & Director (Technical), Sun Teknovation Pvt. Ltd.
Visionary leader driving India’s pharma innovation globally. Expert in turning regulatory challenges into growth opportunities. Leads development of intelligent, future-ready systems that ensure compliance, trust, and scalability. Champion of “Made in India, Trusted Everywhere,” preparing the pharma industry for long-term success.